



Republic of the Philippines  
Department of Health  
**FOOD AND DRUG ADMINISTRATION**



**FDA ADVISORY**

No. 2022-1499-A


25 Aug 2022

**PARA : SA LAHAT NG HEALTHCARE PROFESSIONALS AT SA PUBLIKO**

**PAKSA : Babala sa Publiko Tungkol sa Pagbili at Paggamit ng mga Sumusunod na Hindi Rehistradong Gamot:**

1. Anastrozole Tablets IP Femistra™ 1 x 10 Tablets
2. Aprazer Capecitabine Tablets IP 500 mg Capekast™ 5x10 Tablets
3. Natco Imatinib Capsules I.P. Veenat® 100 120 Capsules


Pinapayuhan ng Food and Drug Administration (FDA) ang publiko laban sa pagbili at paggamit ng mga sumusunod na hindi rehistradong gamot:



**Anastrozole Tablets IP**  
*Femistra™*  
फेमीस्ट्रा

To report adverse events, call toll free on 1800 419 1141 or visit [www.zyduscadila.com](http://www.zyduscadila.com)

**Zydus**  
**Celexa**



**Anastrozole Tablets IP**  
*Femistra™* फेमीस्ट्रा

Each film coated tablet contains anastrozole IP 1 mg. Excipients: q.s. Colour: Titanium Dioxide IP.



Keep in a cool dry place. Dosage: As directed by the Physician. Keep out of reach of children.

<p><b>Anastrozole Tablets IP</b> <i>Femistra™</i></p> <p>Each film coated tablet contains: Anastrozole IP 1 mg Excipients q.s. Colour: Titanium Dioxide IP</p> <p>Keep in a cool dry place Dosage: As directed by the Physician Keep out of reach of children</p> <p><b>CAUTION:</b> Not to be sold by retail without the prescription of a Registered Medical Practitioner.</p>	<table border="0"> <tr><td>Batch No. :</td><td>M102518</td></tr> <tr><td>Mfg. Date :</td><td>02/2021</td></tr> <tr><td>Expiry Date :</td><td>01/2023</td></tr> <tr><td>Maximum Retail Price ₹ :</td><td>366.81</td></tr> <tr><td>Per 10 Tablets (Inclusive of All Taxes)</td><td></td></tr> </table> <p>Mfg. Lic. No.: G/1486</p> <p><b>Zydus</b> Marketed by: Zydus Celexa (A division of Cadila Healthcare Ltd.)</p> <p><b>Celexa</b></p> <p>Manufactured by: <b>Cadila Healthcare Ltd.</b> Survey No. 417, 419 and 420, Sarkhej Bavla N.H. No. 8 A, Village: Moraiya, Tal.: Sanand, Dist.: Ahmedabad-382 210. TM-Trademark applied for</p>	Batch No. :	M102518	Mfg. Date :	02/2021	Expiry Date :	01/2023	Maximum Retail Price ₹ :	366.81	Per 10 Tablets (Inclusive of All Taxes)	
Batch No. :	M102518										
Mfg. Date :	02/2021										
Expiry Date :	01/2023										
Maximum Retail Price ₹ :	366.81										
Per 10 Tablets (Inclusive of All Taxes)											

**Anastrozole Tablets IP Femistra™ 1 x 10 Tablets**  
Manufactured by: Cadila Healthcare Ltd. - Survey No. 417, 419 and 420, Sarkhej Bavla N/H. No. 8 A, Village: Moraiya, Tal.: Sanand, Dist.: Ahmedabad-382 210.  
by: Zydus Celexa (A division of Cadila Healthcare Ltd.)



Larawan 1. Hindi rehistradong gamot





**Aprazer Capecitabine Tablets IP 500 mg Capekast™ 5x10 Tablets**  
 Manufactured by: Aprazer Healthcare Pvt. Ltd.  
 by: Aprazer

Larawan 2. Hindi rehistradong gamot



**NATCO Imatinib Capsules I.P. Veenat® 100 120 Capsules**  
 Manufactured by: Natco Pharma Limited - Plot No. A-3, Upsidc Industrial Area, Selaqui, Dehradun-248 197. Uttarakhand. Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad - 500 034

Larawan 3. Hindi rehistradong gamot

Napatunayan sa pamamagitan ng isinagawang *Post-Marketing Surveillance* (PMS) ng FDA na ang mga nasabing gamot ay hindi dumaan sa proseso ng rehistrasyon ng Ahensya at hindi nabigyan ng kaukulang awtorisasyon tulad ng *Certificate of Product Registration* (CPR). Dahil dito, hindi masisiguro ng Ahensya ang kalidad, kaligtasan at bisa nito. Samakatuwid, ang paggamit ng nasabing mga iligal na produkto ay maaaring magdulot ng panganib sa kalusugan.

Alinsunod sa *Republic Act No. 9711*, o ang *Food and Drug Administration Act of 2009*, ang paggawa, pag-angkat, pagbenta, pamamahagi, paglipat, promosyon, pagpapatalastas o *sponsorship* ng produktong pangkalusugan nang walang kaukulang awtorisasyon mula sa FDA ay ipinagbabawal.

Ang lahat ng establisyamento at/o entidad ay binabalaang huwag mamahagi ng nasabing mga iligal na produkto hanggang sa ito ay mabigyan ng kaukulang awtorisasyon. Karampatang parusa ay mahigpit na ipatutupad sa mga lalabag. Ugaliing tignan kung rehistrado ang produkto sa FDA sa pamamagitan ng *FDA Verification Portal feature* na makikita sa <https://verification.fda.gov.ph>.

Hinihiling sa lahat ng *Local Government Units* (LGUs) at *Law Enforcement Agencies* (LEAs) na tiyaking ang mga produktong ito ay hindi maibebenta o magagamit sa kanilang mga nasasakupan.

Para sa karagdagang impormasyon at katanungan, maaaring mag-*email* sa [info@fda.gov.ph](mailto:info@fda.gov.ph). Upang mag-*report* ng patuloy na pagtitinda o pangangalakal ng mga hindi rehistradong gamot, mag-*email* sa [ereport@fda.gov.ph](mailto:ereport@fda.gov.ph). Maaari ring tumawag sa *Center for Drug Regulation and Research* (CDRR) sa numerong (02) 8809-5596. Para sa mga hinihinalang hindi kanais-nais na reaksyon sa gamot, i-*report* agad sa FDA gamit ang *link* na ito: <https://primary-reporting.who-umc.org/Reporting/Reporter?OrganizationID=PH> at kumpletuhin ang mga kinakailangang impormasyon.

Ang lahat ay hinihikayat na palaganapin ang mga nakasaad na impormasyon.

DTN:   
20220811151350

  
DR. SAMUEL A. ZACATE  
Director General